Bruna Barneda
Chief Operating Officer Ahead Therapeutics
She holds an MSc and PhD in Molecular Biology and Biochemistry from UAB and an MSc in Business Administration from UPF–La Salle BES. With over 12 years of experience in biomedical R&D and expertise in IP and business strategy, she now serves as COO at Ahead, leading strategic planning to align R&D with company goals.
Seminars
Thursday 5th March 2026
Modulating T & B Cell Interactions to Achieve Durable Immune Tolerance in ASIT
11:30 am
- Ahead MiMiTOPs display a broad, cross-disease mechanism of action
- Antigen-presenting cells from patients with T1D, RA, MG, MS and iTTP acquire a tolerogenic phenotype following interaction with MiMiTOPs. Dendritic cells and macrophages become tolerogenic, reducing their ability to drive autoreactive T cell proliferation, while B lymphocytes directly internalize MiMiTOPs and secrete TGF-β and IL-10, adopting an immunoregulatory phenotype
- Through coordinated effects on innate and adaptive immunity, MiMiTOPs provide an antigen-specific strategy to support long-term immune tolerance
NEW DATA
